Simon Faissner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4029765/publications.pdf Version: 2024-02-01

		393982	395343
45	1,155	19	33
papers	citations	h-index	g-index
52	52	52	2020
all docs	docs citations	times ranked	citing authors

SIMON FAISSNED

#	Article	IF	CITATIONS
1	COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. Journal of Neurology, 2022, 269, 1774-1775.	1.8	25
2	Hypoechogenicity of brainstem raphe in long-COVID syndrome–less common but independently associated with depressive symptoms: a cross-sectional study. Journal of Neurology, 2022, 269, 4604-4610.	1.8	4
3	Resurrection of sildenafil: potential for Huntington's Disease, too?. Journal of Neurology, 2022, 269, 5144-5150.	1.8	1
4	The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110306.	1.5	8
5	Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease—Data from a Real World Cohort. Brain Sciences, 2021, 11, 413.	1.1	10
6	Clozapine Regulates Microglia and Is Effective in Chronic Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2021, 12, 656941.	2.2	15
7	Differential Diagnosis of Chorea—HIV Infection Delays Diagnosis of Huntington's Disease by Years. Brain Sciences, 2021, 11, 710.	1.1	4
8	Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany. Neurological Research and Practice, 2021, 3, 42.	1.0	10
9	Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis. Frontiers in Immunology, 2021, 12, 759389.	2.2	6
10	Risk of perioperative neck hematoma in TIA and non-disabling stroke patients with symptomatic carotid artery stenosis undergoing endarterectomy within 14Âdays from cerebrovascular event Journal of the Neurological Sciences, 2020, 409, 116590.	0.3	7
11	Delayed Diagnosis of Anti-Hu Antibodies in a Young Patient With Cerebellar Atrophy. Pediatric Neurology, 2020, 111, 27-29.	1.0	0
12	Endocarditis following ocrelizumab in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	6
13	Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina. Journal of Neuroimmunology, 2020, 342, 577194.	1.1	2
14	Letter to the editor regarding Gholamzad et al., "A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future― Inflammation Research, 2020, 69, 153-153.	1.6	1
15	Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery, 2019, 18, 905-922.	21.5	265
16	Progressive multiple sclerosis: latest therapeutic developments and future directions. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832.	1.5	45
17	General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS. Neurological Research and Practice, 2019, 1, 32.	1.0	5
18	Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e551.	3.1	20

SIMON FAISSNER

#	Article	IF	CITATIONS
19	Smad7 in intestinal CD4 ⁺ T cells determines autoimmunity in a spontaneous model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25860-25869.	3.3	23
20	Oral Therapies for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a032011.	2.9	29
21	Clinical commentary on â€~Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis'. Multiple Sclerosis Journal, 2018, 24, 1385-1386.	1.4	0
22	1,25-OH 2 vitamin D 3 and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL). Leukemia Research Reports, 2018, 9, 38-41.	0.2	3
23	Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs, 2018, 32, 269-287.	2.7	65
24	Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?. Multiple Sclerosis Journal, 2018, 24, 1543-1556.	1.4	33
25	Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. Journal of Neuroinflammation, 2018, 15, 183.	3.1	39
26	Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1415-1422.	1.1	27
27	Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. Journal of Neuroinflammation, 2017, 14, 51.	3.1	31
28	Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nature Communications, 2017, 8, 1990.	5.8	50
29	Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease. Chemical Science, 2017, 8, 5636-5643.	3.7	79
30	Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. Journal of Neurology, 2016, 263, 1092-1098.	1.8	29
31	"Punched nerve syndrome―as contributing factor for "Saturday night palsy― Journal of the Neurological Sciences, 2016, 368, 173-174.	0.3	5
32	Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e285.	3.1	19
33	Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. CNS Neuroscience and Therapeutics, 2016, 22, 1019-1022.	1.9	4
34	Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Therapeutic Advances in Neurological Disorders, 2016, 9, 281-286.	1.5	29
35	Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke. Neurology, 2016, 86, 1103-1111.	1.5	59
36	"Liberation treatment―for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain and Behavior, 2015, 5, 3-12.	1.0	19

SIMON FAISSNER

#	Article	IF	CITATIONS
37	Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e85.	3.1	25
38	Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Therapeutic Advances in Neurological Disorders, 2015, 8, 233-238.	1.5	55
39	Interferon-beta affects mitochondrial activity in CD4 ⁺ lymphocytes: Implications for mechanism of action in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1262-1270.	1.4	10
40	Teaching Neuro <i>Images</i> : Sonographic "retrobulbar spot sign―in differentiating etiologies of sudden visual loss. Neurology, 2014, 82, e153-4.	1.5	2
41	Atypical Occipital Calcinosis in a Caucasian Individual with Probable Diffuse Neurofibrillary Tangles with Calcification. Journal of the American Geriatrics Society, 2014, 62, 2022-2024.	1.3	1
42	Cytoplasmic HIV-RNA in monocytes determines microglial activation and neuronal cell death in HIV-associated neurodegeneration. Experimental Neurology, 2014, 261, 685-697.	2.0	17
43	Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis. Journal of Central Nervous System Disease, 2014, 6, JCNSD.S14049.	0.7	50
44	Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases. Therapeutic Advances in Neurological Disorders, 2014, 7, 289-291.	1.5	6
45	Monitoring Peripheral Blood CD4+ Intracellular Adenosine Triphosphate Concentration in Patients with Psoriasis Treated with Fumaric Acid Esters. Acta Dermato-Venereologica, 2012, 92, 364-366.	0.6	8